Evaluation In- Network & Out-of-Network Pharmacy Trends

In part two of our 2023 drug trends series, we’re evaluating in-network and out-of-network prescription for a total view of prescription activity.

Infographic Summary

Out-of-network prescriptions represent an area of additional opportunity for clinical and cost controls and can often be associated with high-cost drugs. Leveraging both bill review and pharmacy data provides additional visibility into transactions from third-party billers, physician-dispensers, and co-mingled hospital and office visit bills. This analysis features the trends experienced within our combined in- and out-of-network channels to identify a total view of prescription activity.

To view future installments of the drug trends series, be sure to visit our drug trends page.


To learn more from Enlyte, please visit their website.

Enlyte is the parent brand of Mitchell | Genex | Coventry, a leader in cost-containment technology, independent medical exams (IME), provider and specialty networks, case management services, pharmacy benefit and disability management. The three businesses have recently aligned their joint industry expertise and advanced technology solutions into a combined organization of nearly 6,000 associates committed to simplifying and optimizing property, casualty and disability claims processes and services.

More from Risk & Insurance